BioCryst to Announce Fourth Quarter & 2012 Financial Results on February 19, 2013

  BioCryst to Announce Fourth Quarter & 2012 Financial Results on February 19,
  2013

Business Wire

RESEARCH TRIANGLE PARK, N.C. -- February 5, 2013

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that its fourth
quarter and full year 2012 financial results will be released on Tuesday,
February 19, 2013. BioCryst will host a conference call and webcast at 11:00
a.m. Eastern Time to discuss the financial results and to provide an update on
the Company’s programs. The call will be led by Jon P. Stonehouse, President
and Chief Executive Officer, Thomas R. Staab, II, Senior Vice President and
Chief Financial Officer and Dr. William P. Sheridan, Senior Vice President and
Chief Medical Officer.

Links to a live audio webcast and replay of the presentation may be accessed
on the BioCryst website events page at
http://investor.shareholder.com/biocryst/events.cfm.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals designs, optimizes and develops novel small molecule
drugs that block key enzymes involved in infectious and inflammatory diseases,
with the goal of addressing unmet medical needs of patients and physicians.
BioCryst currently has two late-stage development programs: peramivir, a viral
neuraminidase inhibitor for the treatment of influenza, and ulodesine, a
purine nucleoside phosphorylase (PNP) inhibitor for the treatment of gout. In
addition, BioCryst has several early-stage programs: BCX4161 and a next
generation oral inhibitor of plasma kallikrein for hereditary angioedema and
BCX4430, a broad spectrum antiviral for hemorrhagic fevers. For more
information, please visit the Company's website at www.BioCryst.com.

This press release contains forward-looking statements, including statements
regarding future results and achievements. These statements involve known and
unknown risks, uncertainties and other factors which may cause our actual
results, performance or achievements to be materially different from any
future results, performances or achievements expressed or implied by the
forward-looking statements. Please refer to the documents BioCryst files
periodically with the SEC and located at
http://investor.shareholder.com/biocryst/sec.cfm.

BCRXW

Contact:

BioCryst Pharmaceuticals
Robert Bennett, 919-859-7910
 
Press spacebar to pause and continue. Press esc to stop.